Physician profile
Nikesh Batra
NPI 1285689224
$4,033.65
in general payments reported to CMS, 2019-2025
24 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,456 · 2020: $250 · 2022: $21.15 · 2023: $931 · 2024: $19.32 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053 · Travel and Lodging: $234 · Education: $19.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.77 |
| Travel and Lodging | $234.13 |
| Education | $19.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,213.81 | 2019-2020 | |
| Abbott Laboratories | $644.92 | 2019 | |
| Curonix LLC | $522.17 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Boston Scientific Corporation | $254.51 | 2019-2025 | General - Pain Management |
| Spr Therapeutics, INC | $180.56 | 2023 | Sprint Pns System |
| Zoll Respicardia, INC. | $160.93 | 2023 | Remede System |
| Spinesmith Holdings, LLC | $142.21 | 2019 | |
| Scilex Pharmaceuticals INC. | $130.53 | 2019 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Lilly USA, LLC | $121.85 | 2025 | Zepbound |
| Axsome Therapeutics, INC. | $103.74 | 2023 | Auvelity |
| Biodelivery Sciences International, INC. | $95.93 | 2019-2020 | |
| Pfizer INC. | $87.87 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.79 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.34 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $25.07 | 2019 | |
| Medtronic, INC. | $21.15 | 2022 | |
| Amgen INC. | $21.04 | 2019 | |
| Zyla Life Sciences, INC. | $19.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.04 | 2020 | |
| Nevro Corp. | $17.20 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.08 | 2019 | |
| Horizon Therapeutics Plc | $13.16 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikesh Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.